YKL-06-061 is a small molecule serine/threonine-protein kinase SIK1 inhibitor (Ki = 6.56 nM) that is hopefully developed to be a dermatologic drug impacting UV protection and skin cancer risk. It causes a dose-dependent increase in microphthalmia-associated transcription factor (MITF) mRNA expression during 3-hour function in normal human melanocytes, UACC62 human melanoma cells, and UACC257 human melanoma cells.
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cardiovascular and blood system | Salt-inducible Kinases (SIKs)
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.